Skip to main content
SpringerLink
Log in

Bases sémantiques et pharmacologiques d’une nouvelle classification des antipsychotiques

Semantic and pharmacological aspects towards a new classification of antipsychotic drugs

  • Thérapeutiques / Therapeutics
  • Published:
PSN

Résumé

Les grandes étapes du développement des médicaments utilisés pour réduire les expressions psychotiques sont présentées en évoquant les mécanismes d’action sous-jacents. Les termes antipsychotiques, antipsychotiques neuroleptiques, antipsychotiques non neuroleptiques, antipsychotiques non neuroleptiques antidéficitaires sont justifiés et servent de base à la proposition d’une nouvelle classification des antipsychotiques. Il est souligné, enfin, que le terme «neuroleptique atypique» est mal construit, malencontreux, et qu’il devrait, de ce fait, être abandonné.

Abstract

The main stages involved in the development of drugs effective against psychotic manifestations are presented, as well as their mechanisms of action. Justification is given for the terms antipsychotic drugs, neuroleptic antipsychotic drugs, non-neuroleptic antipsychotic drugs, and non neuroleptic antipsychotic drugs, effective against negative expressions of schizophrenia. These constitute the basis of the new classification of antipsychotic drugs suggested. Finally, the term “atypical neuroleptic drugs”, frequently used in France, is described as badly constructed and unfortunate and should therefore be abandoned.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Bressan RA, Erlansson K, Jones HM, et al (2003) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative (123I) epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160: 1413–1420

    Article  PubMed  Google Scholar 

  2. Costentin J (1981) Revue des principaux arguments étayant l’hypothèse d’une hyperactivité dopaminergique dans la schizophrénie. In: Actualités de la schizophrénie. Presse Universitaire de France. collect. Psychiatrie ouverte. Ed Pichot; Chap 11, pp. 169–193

  3. Costentin J, Dubuc I, Protais P (1983) Behavioural data suggesting the plurality of central dopamine receptors. Adv Biochem Psychopharmacol 37:289–297

    PubMed  CAS  Google Scholar 

  4. Delay J, Deniker P (1952) Trente-huit cas de psychoses traitées par la cure prolongée et continue de 4 560 RP. C R Congrès Alien et neurologique de langue française. Paris: Masson

    Google Scholar 

  5. Hall D, Strange P (1997) Evidence that antipsychotic drugs are inverse antagonists at D2 dopamine receptors. Br J Pharmacol 121:731–736

    Article  PubMed  CAS  Google Scholar 

  6. Laborit H, Huguenard P, Alluaume R (1952) Un nouveau stabilisateur neurovégétatif: le 4 560 RP. Presse Med 60:206–208

    PubMed  CAS  Google Scholar 

  7. Matsubara S, Matsubara R, Kusumi I, et al (1983) Dopamine D1, D2 and serotonin 2-receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265: 498–508

    Google Scholar 

  8. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. J Pharmacol Exp Ther 251:238–246

    PubMed  CAS  Google Scholar 

  9. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313

    PubMed  CAS  Google Scholar 

  10. Sen G, Bose KC (1931) Rauwolfia serpentina, a new Indian drug for insanity and high blood pressure. Indian Med World 2:194–201

    Google Scholar 

  11. Sokoloff P, Martres MP, Protais P, et al (1983) Two distinct classes of dopamine receptors mediating actions of antipsychotics: binding and behavioural studies. Adv Biochem Psychopharmacol 36:163–173

    PubMed  CAS  Google Scholar 

  12. Spampinato U, Esposito E, Samanin R (1985) Serotonin agonists reduce dopamine synthesis in the striatum only when the flow of nigro-striatal neurons is intact. J Neurochem 45(3):980–982

    Article  PubMed  CAS  Google Scholar 

  13. Strange P (1999) Agonism and inverse agonism at dopamine D2 like receptors. Clin Exp Pharmacol Physiol supp: 53–59

  14. Sumiyoshi T, Suzuki K, Sakamoto H, et al (1995) Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology 12:57–64

    Article  PubMed  CAS  Google Scholar 

  15. Tadori Y, Miwa T, Tottori K, et al (2005) Aripiprazole’s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515:10–19

    Article  PubMed  CAS  Google Scholar 

  16. Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411–420

    Article  PubMed  CAS  Google Scholar 

  17. Williams J, Davies JA (1983) The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra. J Pharmacol 35(11):734–737

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de neuropsychopharmacologie, CNRS, faculté de médecine et de pharmacie, 22, boulevard Gambetta, F-76183, Rouen, France

    J. Costentin

Authors
  1. J. Costentin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Costentin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costentin, J. Bases sémantiques et pharmacologiques d’une nouvelle classification des antipsychotiques. Psychiatr Sci Hum Neurosci 7, 31–34 (2009). https://doi.org/10.1007/s11836-009-0080-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11836-009-0080-8

Mots clés

Keywords

Search

Navigation